Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

On October 1, 2021 Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), which will be held on November 10-14, 2021 (Press release, Compugen, OCT 1, 2021, https://www.prnewswire.com/news-releases/compugen-to-present-clinical-data-from-anti-tigit-com902-monotherapy-and-triple-combination-dose-escalation-studies-at-sitc-2021-301389580.html [SID1234590667]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: COM902 (anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics, and receptor occupancy in patients with advanced solid tumors (NCT04354246).
Abstract Number: 477
Lead Author: Dumbrava, E, E
Date: Friday, November 12, 2021

Title: COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability, and pharmacokinetics in patients with advanced solid tumors (NCT04570839).
Abstract Number: 478
Lead Author: Dumbrava, E, E
Date: Saturday, November 13, 2021

Title: Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction.
Abstract Number: 252
Lead Author: Alteber, Z
Date: Saturday, November 13, 2021